Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality

Exploring the intention and hesitancy to receive a booster dose of COVID-19 vaccine among patients with comorbid disease conditions using a health belief model

“…Due to the significant and unprecedented public health impact of the global COVID-19 pandemic and associated morbidity and mortality, several preventive measures, such as daily activity restriction, social isolation for several months, and vaccination, are being implemented to strictly control the pandemic. 1 , 2 Comorbidities are associated with poorer health outcomes, more complex clinical care, and increased health care costs. 3 Due to their low immune status, the clinical outcomes and length of hospital stay are directly related to the comorbidities and age of COVID-19 patients.…”

In-silico analysis of nsSNPs in human CYP3A4/5 and their effects on drug-enzymes interactions of FDA-approved COVID-19 antiviral drugs: A pharmacogenetic study

“…ineffective for others 2 . The global efforts to investigate the available antivirals and their efficacy in managing covid-19 disease were challenged by the slower pace of studying the underlying genetic determinants affecting drugs metabolism 3 . Remdesivir and nirmatrelvir/ritonavir drugs are FDA-licensed for treatment of Covid-19 4 .…”